NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Palisade Bio, Inc. (PALI) Stock Analysis

Palisade Bio, Inc. (PALI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PALI

$1.40

−$0.03 (−2.10%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PALI with… →

PALI Key Statistics

As of Oct 21, 2026
Trading
Open
$1.44
Previous Close
$1.43
Day's Range
1.39–1.46
52-Week Range
1.32–2.86
Volume
1.43M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.62
Valuation
Market Cap
$243.98M
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
487.96
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$16.78M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
174.27M
1-Year Return
−20.90%
Dividend and dates
Avg Volume
2.55M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PALI closed at $1.40, −20.90% over 1 year.

Palisade Bio, Inc. (PALI) has a market capitalization of $243.98M.

In fiscal 2025, PALI reported revenue of $0.00.

PALI Stock Return by Calendar Year

Palisade Bio, Inc. (PALI) 10-year return: what $10,000 became

1 year
$10,000 $7,910
−20.90%
5 years
$10,000 $7
−99.93%
10 years
$10,000 $0.04
−99.9996%

If you had invested $10,000 in Palisade Bio, Inc. (PALI) 10 years ago, at the close on October 21, 2016, it would have been worth $0.04 at the close on October 21, 2026: −99.9996% in total, −71.06% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−40.43%
2025+42.42%
2024−81.36%
2023−88.65%
2022−92.00%
2021−75.38%
2020−11.11%
2019−84.03%
2018−81.98%
2017−51.00%
2016 (partial year)+8.00%

As of October 21, 2026.

PALI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$16.78M—
2024$0.00−$14.44M—
2023$250.00K−$12.30M−4,920.0%
2022$0.00−$14.26M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$18.06M−$16.78M—
2024$0.00—−$14.86M−$14.44M—
2023$250.00K—−$12.85M−$12.30M−4,920.0%
2022$0.00—−$15.31M−$14.26M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PALI Valuation vs Biotechnology Median

Median of 608 stocks
MetricPALIBiotechnology medianvs median
P/S ratio487.9613.3036.7x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Palisade Bio, Inc. (PALI) at $243.98M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 14.

The 52-week range on file runs from $1.32 to $2.86. PALI last closed at $1.40 on October 21, 2026. That is −$0.03 (−2.10%) against the previous close. The latest close sits 6.06% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $16.78M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 487.96. On price-to-sales that is 36.7 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.62. Daily returns over the trailing 10 years annualize to a volatility of 140.87%. The trailing one-year total return is −20.90%. Across 10 years the annualized return works out at −71.06%.

Growth & Income

The record shows no dividend for PALI.

So far in 2026 the total return is −40.43%. Across the complete calendar years on file, 2025 returned +42.42% and 2022 returned −92.00%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Palisade Bio, Inc. (PALI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Palisade Bio, Inc. PALI $243.98M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Visit website →